The uncertainties surrounding the most appropriate treatment of breast cancer in BRCA1 and BRCA2 gene carriers is of critical importance and must be resolved in order that clinicians can better tailor treatment in hereditary breast cancer. The gene discussed is BRCA1; the disease is breast cancer.